ArticleMolecular biomedicine2025
Down-regulation of RBM47 due to diminished activation by forkhead box A1 (FOXA1) and silencing by CpG methylation is associated with epithelial-mesenchymal transition and metastasis of colorectal cancer.
Article in Molecular biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Inhibition of RBM23 induces ferroptosis in colon cancer cells via c-Myc regulation.Cancer cell international · 2026Article
- RBM47-Induced Gasdermin A/GSDMA Mediates Mesenchymal-Epithelial Transition and Pyroptosis of Colorectal Cancer Cells.Cancers · 2026Article
- RNA-binding protein RBM47 in health and disease: molecular mechanisms, preclinical evidence, and translational challenges.Frontiers in immunology · 2026Review
- RNA-binding motif proteins as context-dependent regulators of tumor-immune crosstalk, genome stability, and therapeutic vulnerabilities in cancer.Frontiers in immunology · 2026Review
- Claudin-1 Interacts with CD81 and Promotes the Progression of Colorectal Cancer.Oncology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The gene encoding the RNA-binding motif protein 47 (RBM47) is highly expressed in epithelial cells and its down-regulation is characteristic for many types of cancer, among them colorectal cancer (CRC). However, the underlying mechanisms for this differential expression of RBM47 and its functional consequences during CRC progression have remained unknown. Here we found that RBM47 expression progressively decreases during CRC progression and is associated with poor prognosis and the metastatic CRC subtypes CMS4 and CRIS-B. In mice and humans RBM47 expression was highest in endoderm-derived tissues. The expression of forkhead box A1 (FOXA1), a transcription factor essential for the development of endoderm-derived epithelial tissues, showed a positive correlation with RBM47 expression in human tissues, as well as in primary CRCs and derived cell lines. Like RBM47, FOXA1 showed a down-regulation during CRC progression that is associated with poor prognosis and CMS4/CRIS-B. Ectopic FOXA1 induced RBM47 via directly binding to FOXA1 binding sites within the RBM47 promoter region. Up-regulation of RBM47 was necessary for FOXA1-mediated mesenchymal-to-epithelial transition (MET) and inhibition of CRC cell migration and invasion. RBM47 expression was silenced by CpG methylation in mesenchymal-like CRC cell lines. Moreover, epigenetic silencing of RBM47 in primary CRCs was associated with liver metastases. Therefore, the down-regulation of RBM47 is presumably initially mediated by loss of FOXA1 expression and subsequently fixed by CpG methylation of the RBM47 promoter. This down-regulation of RBM47 facilitates EMT and thereby promotes CRC metastasis. Finally, our results show that CpG hypermethylation of the RBM47 promoter represents a potential biomarker for metastatic CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.